FDA Grants Import Discretion of Bracco's Iodinated Contrast Medium

Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage. The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August, 2022.

Kodak Receives FDA Clearance for New DR System

Ultravist (Iopromide) Paves New Path in Breast Cancer Detection - Xtalks

FDA Clears Artis Pheno Angiography System from Siemens Healthineers

Short-, Mid-, and Long-term Strategies to Manage the Shortage of Iohexol

Guerbet Announces ACR Committee on Drugs and Contrast Media Classifies Elucirem (Gadopiclenol) Injection a Group II Agent

Contrast Media Imaging Technology News

FDA Clears GE Healthcare's New Class of Angiography Systems

EHR Interventions for Contrast Media Shortage Impact CT Utilization

Siemens Healthineers Announces FDA Clearance of ARTIS icono ceiling Angiography System

articles • APPLIED RADIOLOGY

Shimadzu Announces First U.S. Trinias Digital Angiography System Installation

Bracco wins EU approval for MRI contrast agent - Medical Device Network

ACIST Features Contrast Injectors, Software

First Nationwide Use of Bracco's VUEWAY (gadopiclenol) Solution for Injection for MRI

articles • APPLIED RADIOLOGY